Instil Bio Q2 2026 net loss $0.63/share; cash $69.9M funds beyond 2027

Instil Bio, Inc.

Cash, equivalents, restricted cash and marketable securities $69.9M at June 30, 2026, down from $76.3M at Dec 31, 2025.
Q2 2026 net loss per share $0.63 (basic/diluted) vs $3.24 in Q2 2025; non-GAAP $0.45 vs $2.88.
R&D expenses $0.3M in Q2 2026 vs $6.7M in Q2 2025; G&A $5.1M vs $6.2M.
In-process R&D expenses nil vs $10.0M in Q2 2025; restructuring charges $0.2M vs $0.5M.
Company evaluating potential acquisitions, in-licensing opportunities for novel therapeutic candidates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.